Evidence map›Paper›PMID 42889040›Full record

ReviewFrontiers in neurology2026

What happens in vagus.

Steven C Cramer

Abstract readReview
In one paragraph

Review in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Steven C CramerDepartment of Neurology, University of California, Los Angeles and California Rehabilitation Institute, Los Angeles, CA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The parasympathetic nervous system is phylogenetically ancient. In humans, the vagus nerve is the brain's only pathway for bidirectional parasympathetic signaling with the thorax, abdomen, and upper pelvis. Unsurprisingly, the vagus nerve has played a significant role in scientific discovery and therapeutic applications, attracting the attention of Galen, Darwin, and Pavlov, among others. For example, Otto Loewi used the vagus nerve to gather data that confirmed Santiago Ramón y Cajal's Neuron Doctrine. This intensive focus has led to a number of clinical advances related to vagus nerve function, including theories about mind-body connections. Interestingly, reducing vagus nerve activity has been a successful strategy for some clinical conditions, such as peptic ulcer disease and obesity. In other conditions, increasing vagus nerve activity has been successful at improving patient outcomes, for example, in refractory seizures, drug-resistant depression, and stroke recovery; in each of these three conditions, the FDA has approved vagus nerve stimulation as a therapeutic intervention. Potential future developments in the therapeutic modulation of vagus nerve activity are discussed, including its role in perinatal brain development; manipulation of the vagus nerve as a portal for CNS access, as suggested in Parkinson's disease; and closed-loop systems that modulate vagus nerve activity in response to measurement of various forms of signaling, an approach that would be aided by the capacity to directly measure activity in individual vagus nerves.

Indexed as

Vagus NerveVagus Nerve StimulationAnimalsBrainHumansdepressionparasympatheticseizurestroke recoveryvagus nervevagus nerve stimulation

Identifiers

PMID42889040
PMCPMC13668742

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.